Apoferritin: nanocarrier for targeted drug delivery

Routine cancer treatment often causes damage to whole human organism, because cytostatic drugs, which are used during the treatment and whose function is to stop growth of cancer cells, affect also healthy cells and untargeted tissues. Due to this fact, nanocarriers and targeted drug delivery have been recently studied. Side effects and organ damage can be reduced by using nanocarriers and targeted drug delivery. The aim of this assay was to monitor and characterize apoferritin as a nanocarrier for targeted drug delivery. In this work the surface of nanocarrier composed of apoferritin with encapsulated doxorubicin was modified with gold nanoparticles or chloroauric acid, conjugated with linker (HWR peptide) because of correct binding of the antibody and labeled with specific antibody. In this assay the resulting nanocarrier was studied with gel electrophoresis and fluorescent methods.

Fig. 1: The affinity of the gold to the SH groups of cysteine Fig. 2: Effect of modification of gold nanoparticles Fig. 3: The effect of using HWR peptide Fig. 4: The effect of using IgG antibodies Fig. 5: Effect of concentration of anti-IgG antibodies

1. Ferrari M.: Nature Reviews Cancer, 5, 161 (2005).
2. Chomoucka J., Drbohlavova J., Huska D., Adam V., Kizek R., Hubalek J.: Pharmacological Research, 62, 144 (2010).
3. Drbohlavova J., Chomoucka J., Adam V., Ryvolova M., Eckschlager T., Hubalek J., Kizek R.: Current Drug Metabolism, 14, 547 (2013).
4. Kawasaki E. S., Player A.: Nanomedicine: Nanotechnology, Biology and Medicine, 1, 101 (2005).
5. Patra C. R., Bhattacharya R., Mukhopadhyay D., Mukherjee P.: Advanced Drug Delivery Reviews, 62, 346 (2010).
6. Hu Y. R., Li K., Wang L., Yin S. S., Zhang Z. Z., Zhang Y.: Journal of Controlled Release, 144, 75 (2010).
7. Malam Y., Loizidou M., Seifalian A. M.: Trends in Pharmacological Sciences, 30, 592 (2009).
8. Marchal F., Pic E., Pons T., Dubertret B., Bolotine L., Guillemin F.: Bulletin Du Cancer, 95, 1149 (2008).
9. Mishra B., Patel B. B., Tiwari S.: Nanomedicine-Nanotechnology Biology and Medicine, 6, 9 (2010). 10. Gu F. X., Karnik R., Wang A. Z., Alexis F., Levy-Nissenbaum E., Hong S., Langer R. S., Farokhzad O. C.: Nano Today, 2, 14 (2007).
11. Wang J. Q., Sui M. H., Fan W. M.: Current Drug Metabolism, 11, 129 (2010).
12. Sumer B., Gao J. M.: Nanomedicine, 3, 137 (2008).
13. Svenson S.: Molecular Pharmaceutics, 10, 848 (2013).
14. Janu L., Stanisavljevic M., Krizkova S., Sobrova P., Vaculovicova M., Kizek R., Adam V.: Electrophoresis, 34, 2725 (2013).

PDF